Depression has been strongly associated with poor HIV treatment adherence, but little research has explored how individuals manage to follow their regimens despite symptoms of major depression. Using a sample of antiretroviral therapy patients with clinically significant depressive symptoms (n = 84), we examined whether patients with optimal adherence differed from those with suboptimal adherence in terms of the types of depressive symptoms experienced and treatment self-efficacy. There were no significant differences between participants with regard to types of depressive symptoms. Findings indicate that patients with high treatment self-efficacy were more likely to report optimal levels of adherence than patients with low self-efficacy.
AmmassariAAntinoriAAloisiMS. (2004) Depressive symptoms, neurocognitive impairment, and adherence to highly active antiretroviral therapy among HIV-infected persons. Psychosomatics45(5): 394–402.
2.
AntoniMHCarricoAWDuránRE. (2006) Randomized clinical trial of cognitive behavioral stress management on human immunodeficiency virus viral load in gay men treated with highly active antiretroviral therapy. Psychosomatic Medicine68(1): 143–151.
3.
AntonovskyA (1987) Unraveling the Mystery of Health: How People Manage Stress and Stay Well. San Francisco, CA: Jossey-Bass.
4.
BanduraA (1986) Social Foundations of Thought and Action: A Social Cognitive Theory. Englewood Cliffs, NJ: Prentice Hall.
5.
BanduraA (1997) Self-Efficacy: The Exercise of Control. New York: Freeman.
6.
BingEGBurnamMLongshoreD. (2001) Psychiatric disorders and drug use among human immunodeficiency virus-infected adults in the United States. Archives of General Psychiatry58(8): 721–728.
7.
BottonariKATripathiSPFortneyJC. (2012) Correlates of antiretroviral and antidepressant adherence among depressed HIV-infected patients. AIDS Patient Care and STDs26(5): 265–273.
8.
BrownJLLittlewoodRAVanablePA (2013) Social-cognitive correlates of antiretroviral therapy adherence among HIV-infected individuals receiving infectious disease care in a medium-sized northeastern US city. AIDS Care25(9): 1149–1158.
9.
CargillVA (2013) Linkage, engagement, and retention in HIV care among vulnerable populations: “I’m sick and tired of being sick and tired.”Topics in Antiviral Medicine21(4): 133–137.
10.
CargillVAStoneVERobinsonMR (2004) HIV treatment in African Americans: Challenges and opportunities. Journal of Black Psychology30(1): 24–39.
11.
CarricoAWAntoniMHWeaverKE. (2005) Cognitive-behavioural stress management with HIV-positive homosexual men: Mechanisms of sustained reductions in depressive symptoms. Chronic Illness1(3): 207–215.
12.
CatzSLKellyJABogartLM. (2000) Patterns, correlates, and barriers to medication adherence among persons prescribed new treatments for HIV disease. Health Psychology19(2): 124–133.
13.
ChesneyMAIckovicsJRChambersDB. (2000) Self-reported adherence to antiretroviral medications among participants in HIV clinical trials: The AACTC Adherence Instruments. AIDS Care23(3): 255–266.
14.
CieslaJARobertsJE (2001) Meta-analysis of the relationship between HIV infection and risk for depressive disorders. American Journal of Psychiatry158(5): 725–730.
15.
De BruinMViechtbauerWSchaalmaHP. (2010) Standard care impact on effects of highly active antiretroviral therapy adherence interventions: A meta-analysis of randomized controlled trials. Archives of Internal Medicine170(3): 240–250.
16.
DimaALSchweitzerA-MDiaconiţǎR. (2013) Adherence to ARV medication in Romanian young adults: Self-reported behaviour and psychological barriers. Psychology, Health & Medicine18(3): 343–354.
17.
EnselWM (1986) Measuring depression: The CES-D Scale. In: LinNDeanAEnselWM (eds) Social Support, Life Events, and Depression. New York: Academic Press, pp. 51–70.
18.
GiffordALLorigKChesneyM. (1996) Patient education to improve health-related quality of life in HIV/AIDS: A pilot study. In:11th international conference on AIDS, Vancouver, BC, Canada, 7–12 July.
19.
GonzalezJSBatchelderAWPsarosC. (2011) Depression and HIV/AIDS treatment non-adherence: A review and meta-analysis. Journal of Acquired Immune Deficiency Syndromes58(2): 181–187.
20.
HoustonEMcKirnanDCervoneD. (2012) Assessing treatment motivation among patients receiving antiretroviral therapy: A multidimensional approach. Psychology & Health27(6): 674–87.
21.
HoustonEMcKirnanDJ (2010, May) HIV medication management: How do urban poor women stick with antiretroviral therapy?Poster session presented at 22nd annual convention of the Association for Psychological Science, Boston, MA.
22.
Jean-BaptisteR (2008) Factors Associated with Adherence to Antiretroviral Therapy in Rwanda: A Multi-Site Study—Operations Research Results (published for the U.S. Agency for International Development (USAID) by the Quality Assurance Project). Bethesda, MD: University Research Co., LLC.
23.
KobasaSCMaddiSRCouringtonS (1981) Personality and constitution as mediators in the stress-illness relationship. Journal of Health and Social Behavior22(4): 368–378.
24.
McDowellINewellC (1996) Measuring Health: A Guide to Rating Scales and Questionnaires (2nd edn). New York: Oxford University Press.
25.
MaciejewskiPPrigersonHMazureC. (2000) Self-efficacy as a mediator between stressful life events and depressive symptoms: Differences based on history of prior depression. The British Journal of Psychiatry176: 373–378.
26.
MaedaUShenBSchwarzE. (2013) Self-efficacy mediates the associations of social support and depression with treatment adherence in heart failure patients. International Journal of Behavioral Medicine20(1): 88–96.
27.
MarcLGTestaMAWalkerAM.; ACTG Data Analysis Concept Sheet Study Team (2007) Educational attainment and response to HAART during initial therapy for HIV-1 infection. Journal of Psychosomatic Research63: 207–216.
28.
MillettG (2013) Disparities in HIV treatment engagement, adherence, and outcomes. Presentation at the 8th annual meeting of the international conference on HIV treatment and prevention adherence, Miami, FL. Available at: http://www.iapac.org/AdherenceConference/presentations/ADH8_Plenary_Millett.pdf (accessed 12 May 2014).
29.
MillsEJNachegaJBBangsbergDR. (2006) Adherence to HAART: A systematic review of developed and developing nation patient reported barriers and facilitators. PLoS Medicine3(11): 2039–2064.
30.
MuñozMFinneganKZeladitaJ. (2010) Community-based DOT-HAART accompaniment in an urban resource-poor setting. AIDS and Behavior14(3): 721–730.
31.
NewcombMEBedoyaCBlashillAJ. (2014) Description and demonstration of cognitive behavioral therapy to enhance antiretroviral therapy adherence and treat depression in HIV-infected adults. Cognitive and Behavioral Practice. Epub ahead of print 2March. DOI: 10.1016/j.cbpra.2014.02.001.
32.
NokesKJohnsonMOWebelA. (2012) Focus on increasing treatment self-efficacy to improve human immunodeficiency virus treatment adherence. Journal of Nursing Scholarship44(4): 403–410.
33.
OrlandoMBurnamMABeckmanR. (2002) Re-estimating the prevalence of psychiatric disorders in a nationally representative sample of persons receiving care for HIV: Results from the HIV Cost and Services Utilization Study. International Journal of Methods in Psychiatric Research11: 75–82.
34.
PandyaRMetzLPattenSB (2005) Predictive value of the CES-D in detecting depression among candidates for disease-modifying multiple sclerosis treatment. Psychosomatics46(2): 131–134.
35.
PolissetJAmetonouFArriveE. (2009) Correlates of adherence to antiretroviral therapy in HIV-infected children in Lomé, Togo, West Africa. AIDS and Behavior13(1): 23–32.
36.
RadloffLS (1977) The CES-D scale: A self-report depression scale for research in the general population. Applied Psychological Measurement1(3): 385–401.
37.
RajaSMcKirnanDGlickN (2007) The Treatment Advocacy Program–Sinai: A peer-based HIV prevention intervention for working with African American HIV-infected persons. AIDS and Behavior11(5 Suppl.): S127–S137.
38.
ReynoldsNRTestaMAMarcLG. (2004) Factors influencing medication adherence beliefs and self-efficacy in persons naive to antiretroviral therapy: A multicenter, cross-sectional study. AIDS and Behavior8(2): 141–150.
39.
SafrenSAO’CleirighCTanJY. (2009) A randomized controlled trial of cognitive behavioral therapy for adherence and depression (CBT-AD) in HIV-infected individuals. Health Psychology28(1): 1–10.
40.
SafrenSAOttoMWWorthJL. (2001) Two strategies to increase adherence to HIV antiretroviral medication: Life-steps and medication monitoring. Behaviour Research and Therapy39(10): 1151–1162.
41.
SánchezAMartinezMMiroEMedinaA. (2011) Predictors of the pain perception and self-efficacy for pain control in patients with fibromyalgia. The Spanish Journal of Psychology14(1):366–373.
42.
ScheierMFCarverCS (1985) Optimism, coping, and health—Assessment and implications of generalized outcome expectancies. Health Psychology4(3): 219–247.
43.
SchilderAJKennedyCGoldstoneIL. (2001) “Being dealt with as a whole person.” Care seeking and adherence: The benefits of culturally competent care. Social Science & Medicine52: 1643–1659.
44.
SherrLClucasCHardingR. (2011) HIV and depression—A systematic review of interventions. Psychology, Health & Medicine16(5): 493–527.
45.
SiegelKKarusDSchrimshawEW (2000) Racial differences in attitudes toward protease inhibitors among older HIV-infected men. AIDS Care12(4): 423–434.
46.
SimoniJMHuhDWilsonIB. (2012) Racial/ethnic disparities in ART adherence in the United States: Findings from the MACH14 Study. Journal of Acquired Immune Deficiency Syndromes60(5): 466–472.
47.
SimoniJMWiebeJSSaucedaJA. (2013) A preliminary RCT of CBT-AD for adherence and depression among HIV-positive Latinos on the U.S.–Mexico border: The Nuevo Día study. AIDS and Behavior17(8): 2816–2829.
48.
SpringerSADushajAAzarMM (2012) The impact of DSM-IV mental disorders on adherence to combination antiretroviral therapy among adult persons living with HIV/AIDS: A systematic review. AIDS and Behavior16(8): 2119–2143.
49.
SteeleCBMeléndez-MoralesLCampoluciR. (2007) Health Disparities in HIV/AIDS, Viral Hepatitis, Sexually Transmitted Diseases, and Tuberculosis: Issues, Burden, and Response. A Retrospective Review, 2000–2004. Atlanta, GA: Department of Health and Human Services, Centers for Disease Control and Prevention. Available at: http://www.cdc.gov/nchhstp/healthdisparities (accessed 12 May 2014).
50.
ThrasherADEarpJLGolinCE. (2008) Discrimination, distrust, and racial/ethnic disparities in antiretroviral therapy adherence among a national sample of HIV-infected patients. Journal of Acquired Immune Deficiency Syndromes49(1): 84–93.
51.
WagnerGJGogginKRemienRH. (2011) A closer look at depression and its relationship to HIV antiretroviral adherence. Annals of Behavioral Medicine42(3): 352–360.
52.
WattMHMamanSEarpJA. (2009) “It’s all the time in my mind:” Facilitators of adherence to antiretroviral therapy in a Tanzanian setting. Social Science & Medicine68(10): 1793–1800.
53.
WendorfARMosackKE (2013) Navigating hazardous conditions: Understanding HIV medication adherence in the context of depression. Qualitative Health Research23(4): 541–554.
54.
WilsonKJDoxanakisAFairleyCK (2004) Predictors of non-adherence to antiretroviral therapy. Sexual Health1(4): 251–257.
55.
ZichJMAttkissonCCGreenfieldTA (1990) Screening for depression in primary care clinics: The CES-D and the BDI. The International Journal of Psychiatry in Medicine20(3): 259–277.
